SCHEMBL2597849

SCHEMBL2597849

CN(C)CCNC(=O)Nc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.64
POLB P06746 1/20 0.64
EPHX1 P07099 5/20 0.59
ALDH1A1 P00352 1/20 0.59
KDM4E B2RXH2 2/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
LMNA P02545 1/20 0.55
ATM Q13315 2/20 0.54
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
EPHX2 P34913 1/20 0.53
CDK9 P50750 1/20 0.53
CLK4 Q9HAZ1 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7507650 0.90 EPHX1 (0.65) HTTPOLBEPHX1ALDH1A1KDM4E
SCHEMBL12974617 0.86 EPHX1 (0.60) HTTPOLBEPHX1ALDH1A1KDM4E
SCHEMBL13122989 0.85 HTT (0.67) HTTPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL7514779 0.84 EPHX1 (0.61) HTTPOLBEPHX1ALDH1A1KDM4E
SCHEMBL24381846 0.83 POLB (0.65) HTTPOLBALDH1A1SMN1; SMN2MEN1
SCHEMBL3766614 0.83 POLB (0.61) HTTPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL2275794 0.83 POLB (0.68) HTTPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL11051077 0.83 EPHX1 (0.70) HTTPOLBEPHX1ALDH1A1KDM4E
SCHEMBL11262889 0.82 MEN1 (0.46) HTTPOLBALDH1A1MEN1KMT2A
SCHEMBL10551696 0.82 EPHX1 (0.63) HTTEPHX1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571871-B1 Process for the preparation of chiral triazolones SANDOZ AG (CH) 2017-06-21 EP claimed
EP-2571847-B1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES SANDOZ AG (CH) 2016-09-21 EP claimed
US-20130210833-A1 PROCESS FOR THE PREPARATION OF CHIRAL TRIAZOLONES SANDOZ AG (CH) 2013-08-15 US claimed
US-20130203993-A1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES SANDOZ AG (CH) 2013-08-08 US claimed
EP-2571871-A1 PROCESS FOR THE PREPARATION OF CHIRAL TRIAZOLONES Sandoz AG (CH) 2013-03-27 EP claimed
EP-2571847-A1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES Sandoz AG (CH) 2013-03-27 EP claimed
CN-102906087-A Process for the preparation of chiral triazolones SANDOZ AG 2013-01-30 CN claimed
CN-102892750-A Process for the preparation of chiral hydrazides SANDOZ AG 2013-01-23 CN claimed
WO-2011144653-A1 PROCESS FOR THE PREPARATION OF CHIRAL TRIAZOLONES SANDOZ AG (CH) 2011-11-24 WO claimed
WO-2011144655-A1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES SANDOZ AG (CH) 2011-11-24 WO claimed
EP-4683909-A2 ATM KINASE INHIBITORS Eberhard Karls Universität Tübingen (DE) 2026-01-28 EP disclosed
US-20260015328-A1 ATM KINASE INHIBITORS EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) 2026-01-15 US disclosed
WO-2024194460-A2 ATM KINASE INHIBITORS EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) 2024-09-26 WO disclosed
EP-4434972-A1 ATM KINASE INHIBITORS Eberhard-Karls-Universität Tübingen (DE) 2024-09-25 EP disclosed
EP-2721013-B1 PROCESS FOR THE PREPARATION OF A CHIRAL COMPOUND SANDOZ AG (CH) 2018-02-21 EP disclosed
WO-2012172015-A1 PROCESS FOR THE PREPARATION OF A CHIRAL COMPOUND SANDOZ AG (CH) 2012-12-20 WO disclosed
WO-2011144655-A1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES SANDOZ AG (CH) 2011-11-24 WO disclosed
WO-2011144653-A1 PROCESS FOR THE PREPARATION OF CHIRAL TRIAZOLONES SANDOZ AG (CH) 2011-11-24 WO disclosed
US-4352913-A EPOXY RESIN CURING AGENTS CIBA-GEIGY CORPORATION (US) 1982-10-05 US disclosed
US-4324739-A CURING AGENTS FOR POLYEPOXIDES CIBA-GEIGY CORPORATION (US) 1982-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203993-A1 PROCESS FOR THE PREPARATION OF CHIRAL HYDRAZIDES CYP3A5, CYP51A1, CYP3A4 HTT 2309/4885POLB 1537/4885EPHX1 1588/4885
US-20130210833-A1 PROCESS FOR THE PREPARATION OF CHIRAL TRIAZOLONES CYP3A4, CYP3A43, CYP3A5 HTT 4626/4885POLB 902/4885EPHX1 3365/4885
US-20260015328-A1 ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 HTT 2555/4885POLB 151/4885EPHX1 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.